Publications

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Zhu D. et al, (2025), Am J Kidney Dis

Changing paradigms of studies in kidney diseases.

Levin A. et al, (2025), Kidney Int, 108, 1002 - 1017

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.

Herrington WG. et al, (2025), Lancet Diabetes Endocrinol, 13, 1003 - 1014

Glucose Interference in Urine Biomarkers and Implications for Sodium-Glucose Cotransporter 2 Inhibition.

Malijan GB. et al, (2025), Kidney Int Rep, 10, 4090 - 4093

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.

Malijan GB. et al, (2025), Am J Kidney Dis

Lancet Seminar Chronic kidney disease

HERRINGTON W. et al, (2025), The Lancet

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.

Zhou J. et al, (2025), EClinicalMedicine, 85

Time Course of Kidney Injury Biomarkers in Children With Septic Shock: Nested Cohort Study Within the Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis Trial.

Weiss SL. et al, (2025), Pediatr Crit Care Med, 26, e816 - e826

The prevention and management of chronic kidney disease among patients with metabolic syndrome.

Zhu D. et al, (2025), Kidney Int, 107, 816 - 824

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.

Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group . et al, (2025), N Engl J Med, 392, 777 - 787

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.

Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79

LDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL

Judge P. et al, (2024), Nephrology Dialysis Transplantation

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.

Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129

Cohort Profile: Indian Study of Healthy Ageing (ISHA-Barshi).

Mhatre SS. et al, (2024), Int J Epidemiol, 53

Search results (55)